Using anti-Mullerian hormone to protect ovarian function during cancer treatments.
Official title: Anti-Mullerian hormone for preserving ovarian function before administration of gonadotoxic therapies or after transplantation of cryopreserved tissue.
Funded at Weill Medical Coll of Cornell Univ · NIH-11084568 · Data updated 2026-11-12
This study is looking at how a hormone called anti-Mullerian hormone (AMH) can help protect the ovaries of women with cancer who need urgent treatment and can't use standard fertility preservation methods, by improving blood flow and supporting healthy egg growth after ovarian tissue is transplanted.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 8, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $364,425 |
| NIH project number | 5R01HD112441-03 |
| Project ID | NIH-11084568 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pre-pubertal girls or women facing immediate chemotherapy who wish to preserve their ovarian function.
✕Less likely to help
Patients who are not undergoing gonadotoxic therapies or those who do not wish to preserve fertility may not benefit from this research.
What this research studies
This research investigates how anti-Mullerian hormone (AMH) can help preserve ovarian function in women undergoing cancer treatments that may harm their fertility. It focuses on patients who cannot undergo traditional fertility preservation methods, such as ovarian hyperstimulation, due to the urgency of their treatment. The study combines the use of cultured vascular cells to improve blood flow to transplanted ovarian tissue with the application of AMH to support healthy follicle growth. By enhancing the viability of ovarian tissue after transplantation, this research aims to improve the chances of fertility preservation for affected women.
Why it matters
Potential benefit: If successful, this research could significantly improve fertility preservation options for women undergoing cancer treatments.
How similar studies have gone: Previous research has shown promise in using hormonal treatments and tissue transplantation to enhance fertility outcomes, indicating potential success for this approach.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: James, Daylon J — Weill Medical Coll of Cornell Univ
- Study coordinator: James, Daylon J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.